Daniel Joseph O’Connell, Chief Executive Officer of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), sold a total of 12,035 shares of the company's stock on January 21 and 22, 2026, as detailed in a recent SEC Form 4 filing. The cumulative proceeds from these sales reached $21,993, executed across multiple tranches to address tax payments associated with the vesting of restricted stock units.
On the first day of transactions, O’Connell sold 9,346 shares at an average price of $1.8112, with individual sale prices ranging between $1.7600 and $1.8800 per share. The following day, he sold an additional 2,689 shares averaging $1.8838 each, with trade prices fluctuating from $1.8700 to $1.9000. These sales were conducted pursuant to a pre-planned Rule 10b5-1 trading strategy, adopted on June 24, 2024.
Post-transaction, O’Connell retains direct ownership of 881,275 shares of Acumen Pharmaceuticals, a company whose stock price currently stands at $1.98. This price reflects an improvement from the 52-week low of $0.86 but remains below the peak of $2.46 over the same period. Fair Value estimates provided by InvestingPro suggest the stock is mildly undervalued at this level.
Acumen Pharmaceuticals recently disclosed a net loss of $26.5 million for the third quarter of 2025. Despite this financial setback, investor interest has been fueled by positive developments in the company’s Alzheimer's therapeutic pipeline. Acumen is advancing its lead drug candidate, Sabirnetug, in collaboration with JCR Pharmaceuticals and has initiated the open-label extension phase of its Phase 2 ALTITUDE-AD clinical trial, enabling participants to continue receiving the treatment for up to 52 weeks.
At the 18th Annual Clinical Trials on Alzheimer’s Disease conference, Acumen highlighted innovative delivery methodologies for its treatment candidates and outlined recruitment strategies that achieved full enrollment of 542 participants in the Phase 2 ALTITUDE-AD study. Market analysts at Stifel have upheld a Buy rating on the stock, citing confidence gained from recent executive engagements regarding the strength of Acumen's drug development pipeline.
From a financial standpoint, Acumen maintains a balance sheet with more cash than debt; however, the company is rapidly utilizing available funds. With a market capitalization around $120 million and analyst price targets spanning $4 to $10, the firm remains under close watch among investors focusing on biotechnology and pharmaceutical sectors.